SEC Filing Summary: AcelRx Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on November 2, 2018. The report addresses a significant corporate event occurring on the same date: the receipt of U.S. Food and Drug Administration (FDA) approval for the company's product, DSUVIA.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on a regulatory milestone rather than periodic financial performance.
Material Changes
The primary material change reported is the regulatory approval of DSUVIA by the FDA. This event marks a pivotal transition for the company, enabling the commercialization of this specific pharmaceutical product.
Outlook and Management Commentary
Management highlighted the FDA approval of DSUVIA as the central event of the report. The filing references a press release (Exhibit 99.1) for further details on the approval. No specific financial guidance, risk factors, or contingencies are detailed within the body of this specific 8-K text.
Investor Verification Checklist
- Verify the specific indications and labeling approved by the FDA for DSUVIA.
- Review the attached press release (Exhibit 99.1) for commercial launch timelines and strategy.
- Assess the potential revenue impact of DSUVIA on the company's future financial statements.
- Confirm the company's current cash position and runway to support commercialization efforts.